Welcome to our dedicated page for Lilly Eli & Co news (Ticker: LLY), a resource for investors and traders seeking the latest updates and insights on Lilly Eli & Co stock.
Eli Lilly and Company (NYSE: LLY) generates frequent news across cardiometabolic health, oncology, immunology, obesity and manufacturing expansion. This page aggregates recent press releases and third-party coverage so readers can follow how Lilly’s medicines, clinical programs and corporate actions are evolving over time.
Recent updates show Lilly reporting Phase 3 results for multiple late-stage assets. In obesity and cardiometabolic health, the company has shared topline data from ATTAIN-MAINTAIN, a Phase 3 trial of orforglipron, an investigational once-daily oral GLP-1 receptor agonist, for weight maintenance after prior treatment with injectable incretin therapies. Lilly has also reported results from TRIUMPH-4, a Phase 3 trial of retatrutide, an investigational triple agonist targeting GIP, GLP-1 and glucagon receptors, in adults with obesity or overweight and knee osteoarthritis, with co-primary endpoints in weight loss and pain reduction.
In immunology, Lilly has announced positive topline results from the TOGETHER-PsA Phase 3b trial, which evaluated concomitant use of Taltz (ixekizumab) and Zepbound (tirzepatide) versus Taltz alone in adults with active psoriatic arthritis and obesity or overweight with at least one weight-related condition. The company reports that the combination met the primary endpoint and all key secondary endpoints, supporting an integrated approach to treating psoriatic arthritis and obesity.
Oncology news includes updated EMBER-3 data for Inluriyo (imlunestrant) as monotherapy and in combination with Verzenio (abemaciclib) in ER-positive, HER2-negative advanced breast cancer, and Phase 3 BRUIN CLL-313 results showing that Jaypirca (pirtobrutinib) significantly reduced the risk of progression or death versus chemoimmunotherapy in treatment-naïve CLL/SLL without 17p deletions.
Corporate and strategic news items cover Lilly’s planned acquisition of Ventyx Biosciences, completion of the Adverum Biotechnologies tender offer, a strategic collaboration with Aktis Oncology, and a major manufacturing investment in a new active pharmaceutical ingredient facility in Huntsville, Alabama. Investors and observers can use this news feed to monitor clinical milestones, regulatory submissions, acquisitions, collaborations, financing activities and manufacturing expansions related to LLY.
Eli Lilly announced favorable results from the Phase 3 monarchE trial for Verzenio (abemaciclib), showing a 28.7% reduction in breast cancer recurrence risk in patients with hormone receptor-positive, HER2-negative early breast cancer when combined with standard adjuvant endocrine therapy.
The results, presented at the 2020 Virtual San Antonio Breast Cancer Symposium, indicated an improvement in invasive disease-free survival at 92.3% versus 89.3% in control. The data involved over 1,400 patients and showed consistent benefits across subgroups. Lilly plans to submit these findings to regulatory authorities by year-end 2020.
Eli Lilly's tirzepatide shows promising results for type 2 diabetes treatment, achieving an A1C reduction of 2.07% and body weight reduction of 9.5 kg in a 40-week trial. More than 51% of participants on the highest dose reached A1C levels below 5.7%, typically seen in non-diabetics. The safety profile is comparable to existing treatments, with gastrointestinal issues being the most common side effects. Tirzepatide is a novel dual GIP/GLP-1 receptor agonist, marking a milestone in diabetes care.
Eli Lilly and Company (NYSE: LLY) has announced it will provide its financial guidance for 2021 on December 15, 2020. The company will host a conference call at 8:30 a.m. Eastern time to elaborate on this guidance, which investors and the media can access via a live webcast on the company's website. Additionally, a replay will be available after the call. Lilly continues to focus on discovering and delivering life-changing medicines, reinforcing its commitment to high-quality healthcare.
Loxo Oncology at Lilly announced promising clinical data for LOXO-305, a selective BTK inhibitor, at the ASH Annual Meeting. The global Phase 1/2 BRUIN trial for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) showed a 63% overall response rate among evaluated patients. LOXO-305 demonstrated consistent efficacy regardless of prior therapies, with ongoing safety data indicating manageable adverse effects. With 88% of CLL/SLL patients remaining on LOXO-305, the company is set to initiate Phase 3 trials in 2021, potentially expanding treatment options for patients resistant to conventional therapies.
On December 5, 2020, Loxo Oncology at Lilly presented promising results from the LOXO-305 Phase 1/2 BRUIN trial for mantle cell lymphoma (MCL) and other B-cell malignancies at the ASH Annual Meeting. LOXO-305, a non-covalent BTK inhibitor, showed a 52% overall response rate (ORR) among 56 efficacy-evaluable MCL patients, including 14 complete responses. The company plans to initiate a Phase 3 trial in early 2021 to compare LOXO-305 to existing BTK inhibitors. Safety data indicates manageable side effects, positioning LOXO-305 as a potential new treatment option for patients with limited alternatives.
The U.S. government has acquired 650,000 doses of Eli Lilly's bamlanivimab (LY-CoV555) for $812.5 million. This brings total government purchases to 950,000 doses, aimed at treating high-risk COVID-19 patients. Deliveries are expected by January 31, 2021, with at least 350,000 doses in December 2020. The updated agreement is anticipated to contribute approximately $500 million in revenue and 25 cents to earnings per share. Despite its emergency use authorization, safety and efficacy of bamlanivimab remain unproven, inviting scrutiny.
Eli Lilly (NYSE: LLY) will attend the Evercore ISI 3rd Annual HealthCONx Conference on December 1, 2020. Michael Mason, the senior vice president, will engage in a virtual fireside chat at 2:40 p.m. ET. Investors can access the live audio webcast through the 'Webcasts & Presentations' section of Lilly's Investor website, with a replay available for 90 days following the event. Founded over a century ago, Lilly is committed to creating high-quality medicines and improving disease management worldwide.
Health Canada has authorized bamlanivimab (LY-CoV555) for treating adults and pediatric patients (12+) with mild to moderate COVID-19 at high risk of severe illness. This authorization is based on BLAZE-1 trial data, showing reduced viral load and symptom rates. Lilly plans to manufacture up to one million doses by year-end 2020 and is pursuing additional global authorizations. While the FDA granted Emergency Use Authorization for bamlanivimab in the U.S., it remains unapproved for any use, emphasizing the need for careful monitoring of its safety and efficacy.
Eli Lilly and Incyte announced that the FDA granted an Emergency Use Authorization (EUA) for baricitinib in combination with remdesivir for hospitalized patients with COVID-19 requiring supplemental oxygen. This is the second Lilly therapy to receive EUA for COVID-19 treatments. In clinical trials, the combination showed a 12.5% reduction in recovery time and a 35% decrease in mortality compared to remdesivir alone. Despite this progress, the use remains temporary, pending further evaluation of baricitinib's efficacy and safety.
Eli Lilly and Ypsomed have entered a global agreement to develop an automated insulin delivery system. Lilly will commercialize a version of Ypsomed's mylife™ YpsoPump®, already marketed in Europe since 2016. This system will also incorporate continuous glucose monitoring and utilize pre-filled cartridges for Lilly's rapid-acting insulins. Ypsomed aims for FDA clearance in 2022. With diabetes affecting over 34 million Americans, this partnership seeks to enhance diabetes management options.
FAQ
What is the current stock price of Lilly Eli & Co (LLY)?
What is the market cap of Lilly Eli & Co (LLY)?
